Загрузка...
Application of CRISPR/Cas9 Technology to HBV
More than 240 million people around the world are chronically infected with hepatitis B virus (HBV). Nucleos(t)ide analogs and interferon are the only two families of drugs to treat HBV currently. However, none of these anti-virals directly target the stable nuclear covalently closed circular DNA (c...
Сохранить в:
| Главные авторы: | , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
MDPI AG
2015-11-01
|
| Серии: | International Journal of Molecular Sciences |
| Предметы: | |
| Online-ссылка: | http://www.mdpi.com/1422-0067/16/11/25950 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|